HanchorBio Invited to Present at the 9th BPD Biopharmaceutical Process Development Conference on Next-Generation Drug Manufacturing and CMC Development
Executive Director of CMC Vivian Kuo to join industry experts from Sanofi, Henlius, Hengrui Pharma and other leading companies, highlighting HanchorBio’s integrated capabilities spanning innovative molecule design, process development and clinical supply
[Taipei, Shanghai, San Francisco | August 5, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that Vivian Kuo, PhD, Executive Director of CMC, has been invited to speak at the 2026 9th BPD Biopharmaceutical Process Development Conference.
Dr. Kuo will deliver a presentation entitled “From Complexity to Control: Process and CMC Excellence for Next-Generation Innovative Therapeutics,” sharing HanchorBio’s practical experience in establishing developable, scalable and transferable process and chemistry, manufacturing and controls (CMC) capabilities for increasingly complex next-generation biologics. The conference will be held from August 6 to 7, 2026, at the Zhangjiang Science Hall in Shanghai.
The BPD Biopharmaceutical Process Development Conference focuses on the full development pathway from process development through commercial manufacturing, covering antibodies, fusion proteins, cell and gene therapies, quality management and intelligent manufacturing. As innovative biologic molecules become increasingly complex, process and CMC development must integrate molecular characteristics, product quality, manufacturing scale-up and regulatory requirements at an earlier stage, providing an essential foundation for advancing innovative therapies through clinical development and realizing their full product potential.
HanchorBio’s proprietary FBDB™ (Fc-Based Designer Biologics) platform is designed to generate multifunctional innovative fusion proteins. To address the complexity of these molecules in expression, purification, analytical characterization and quality control, the Company integrates molecular design, cell-line and process development, analytical methods, quality management and clinical supply. This approach enables the CMC team to participate in product strategy from the early stages of research and development, helping reduce uncertainty during scale-up, technology transfer and clinical development.
HCB101 provides one example of HanchorBio’s process-development capabilities. Through process optimization, the Company increased protein titer from an initial 0.8 g/L to 4.6 g/L, with further improvement reaching 6.5–7 g/L. The overall process recovery rate reached 80.7%, while product purity exceeded 99%, demonstrating HanchorBio’s capabilities in improving productivity, recovery efficiency and quality control.
Dr. Kuo’s presentation will examine development trends in next-generation therapeutic platforms and the process and CMC challenges associated with novel molecular formats. She will also discuss how HanchorBio applies cross-functional collaboration, process understanding and risk management to convert complex molecules into controlled and reproducible manufacturing processes. In addition, the presentation will explore how artificial intelligence and data analytics can deepen drug and process understanding and improve development decision-making.
Presentation Details
- Date: August 6, 2026
- Time: 3:20–3:40 p.m.
- Venue: Hall 3, Zhangjiang Science Hall, Shanghai
- Session: Process Development and Validation — Downstream Process Development for Novel Antibodies
- Presentation: “From Complexity to Control: Process and CMC Excellence for Next-Generation Innovative Therapeutics”
- Speaker: Vivian Kuo, PhD, Executive Director of CMC, HanchorBio
HanchorBio’s invitation to participate in the BPD conference reflects the practical experience the Company has accumulated in the process development of complex fusion proteins and next-generation biologics. Through in-depth exchanges with industry experts and upstream and downstream partners, HanchorBio aims to further strengthen its integrated capabilities from innovative molecule design and process development through clinical translation, while expanding opportunities for technology collaboration, co-development, process partnerships and global supply-chain cooperation.
HanchorBio believes that differentiated innovative molecules must be supported by robust CMC capabilities to advance clinical development effectively and support future product commercialization. The Company will continue to focus on product quality, process control and global development requirements while strengthening its CMC platform and cross-regional collaboration capabilities to provide more comprehensive development support for both its internal pipeline and potential partnership programs.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. Company’s proprietary Fc-based designer biologics (FBDB™) platform enables the engineering of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and address limitations of current immunotherapies.
HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations, translational development strategies, and scalable CMC capabilities.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s research collaborations, development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions, regulatory decisions, protocol development, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康生技受邀出席第九屆 BPD 生物藥工藝發展大會 分享下一代創新藥製程與 CMC 開發實務
CMC 執行總監郭孟薇將與賽諾菲、復宏漢霖、恒瑞醫藥等產業專家同台交流，展現漢康生技從創新分子設計、製程開發到臨床供應的整合能力
【台北、上海、舊金山，2026 年 8月 5 日】－全球臨床階段生技公司漢康-KY（HanchorBio，TWSE：7827）宣布，公司 CMC 執行總監郭孟薇博士將受邀出席「2026 BPD 第九屆生物藥工藝發展大會」，並以「從複雜性走向可控：面向下一代創新藥的製程與 CMC 卓越能力」為題發表專題演講，分享漢康生技因應下一代創新生物藥分子複雜度，建立可開發、可放大及可轉化之製程與 CMC（化學、製造與控制）能力的實務經驗。該大會將於 2026 年 8 月 6 日至 7 日在上海張江科學會堂舉行。
BPD 生物藥工藝發展大會聚焦生物藥從製程開發至商業化生產的完整流程，涵蓋抗體、融合蛋白、細胞與基因治療、品質管理及智慧製造等議題。隨著新型生物藥分子日益複雜，製程與 CMC 開發也必須更早整合分子特性、品質、放大生產及法規需求，成為創新藥順利推進臨床與實現產品價值的重要基礎。
漢康生技以自主建立的 FBDB™（Fc-Based Designer Biologics）技術平台為核心，開發具多功能的創新融合蛋白。面對此類分子在表達、純化、分析及品質控制上的高度複雜性，公司持續整合分子設計、細胞株與製程開發、分析方法、品質管理及臨床供應等環節，使 CMC 團隊能從研發早期即參與產品策略，降低後續放大、技術轉移與臨床開發過程中的不確定性。
以 HCB101 為例，漢康生技透過製程優化，已將蛋白產量由早期的 0.8 g/L 提升至 4.6 g/L，最高可達 6.5–7 g/L；整體回收率達 80.7%，產品純度亦可提升至 99% 以上，展現公司在提升產量、回收效率與品質控制方面的 CMC 實力。
郭孟薇博士此次演講將從下一代創新藥物平台的發展趨勢出發，說明新型分子對製程與 CMC 開發帶來的挑戰，以及漢康生技如何透過跨部門協作、製程理解與風險管理，逐步將複雜分子轉化為可控制、可重現的製造流程；同時亦將探討人工智慧及資料分析工具如何協助團隊加深對藥物與製程的理解，提升開發決策效率。
2026 BPD 第九屆生物藥工藝發展大會 演講資訊：
- 日期：2026 年 8 月 6 日
- 時間：15:20–15:40
- 地點：上海張江科學會堂，會場三
- 專場主題：工藝開發與驗證——新型抗體下游工藝開發
- 講題：從複雜性走向可控：面向下一代創新藥的製程與 CMC 卓越能力
- 講者：郭孟薇博士，漢康生技 CMC 執行總監
此次受邀參與 BPD 大會，反映漢康生技在複雜融合蛋白及下一代生物藥製程開發方面所累積的實務經驗。公司期望透過與產業專家及上下游合作夥伴的深度交流，持續強化從創新分子、製程開發到臨床轉化的整合能力，並拓展技術合作、共同開發、製程協作及全球供應鏈合作機會。
漢康生技表示，具差異化的創新分子必須搭配穩健的 CMC 能力，才能有效推進臨床開發並支持未來產品化。公司將持續以產品品質、製程可控性與全球開發需求為核心，深化自身 CMC 平台與跨區域合作布局，為內部產品線及潛在合作專案提供更完整的開發支持。
關於漢康-KY：
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康-KY”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDB多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康-KY的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。
聲明：
本新聞稿及同時發佈之相關資訊內含有預測性敘述；其內容乃根據既有之風險及可能的不確定性進行判斷及預測，包括：市場因素與其他非漢康-KY（以下簡稱本公司）所能掌控之原因。這些預測性敘述是基於現況的預測和評估，除非基於法律的要求，本公司不負日後更新之責。